20/20 Biolabs, Inc. Approves Charter Amendment to Increase Shares

What Happened

• 20/20 Biolabs, Inc. announced that at the adjourned annual meeting on September 16, 2026, its stockholders approved Proposal 3, an amendment and restatement of the Second Amended and Restated Certificate of Incorporation to increase authorized common stock from 50,000,000 shares to 500,000,000 shares. The annual meeting had been originally convened on August 18, 2026 and was adjourned as to this proposal. The company’s definitive proxy statement was dated June 23, 2026 and is incorporated by reference.

Key Details

• Record date: June 22, 2026 (12,251,198 shares outstanding and entitled to vote).
• Quorum: 4,256,837 shares were represented in person or by proxy at the adjourned meeting.
• Final vote on Proposal 3: For — 3,028,609; Against — 1,155,607; Abstentions — 72,621.

Why It Matters

• The approved charter amendment substantially increases the number of authorized common shares (10x), giving the company greater flexibility to issue equity for financing, acquisitions, stock-based compensation, or other corporate purposes. For current and prospective investors, this action can enable future capital-raising but also creates the potential for dilution if new shares are issued. The 8-K provides the voting results and procedural details; no other financial results or management changes were reported in this filing.